Tag: Zydus
Zydus to acquire 50% stake in Sterling Biotech to enter into...
Post this transaction, Sterling Biotech will become a 50:50 Joint Venture with equal representation on the Board
Zydus secures Mexico’s COFEPRIS approval for its biosimilar ‘Bhava’ to treat...
Zydus Lifesciences receives approval to market Bhava™ for various cancers in Mexico, expanding access to affordable oncology treatments
Sentynl Therapeutics, a Zydus Group company announces global acquisition of Zokinvy
Zokinvy is approved in the US, European Union and Great Britain, and Japan for the treatment of Progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients
Zydus receives WHO’s approval for ‘Usnoflast’ as recommended name for ZYIL1
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Zydus gets USFDA nod for Phase II clinical trial of ZYIL1...
The Phase 2 study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with Parkinson’s Disease
Zydus acquires UK based LiqMeds
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026 depending on achievement of certain agreed milestones towards acquisition of the LiqMeds Group of companies
Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a potential...
The USFDA has granted Zydus an ‘Orphan Drug Designation’ for ZYIL1 to treat patients with Cryopyrin Associated Periodic Syndrome (CAPS), a rare auto-inflammatory disease
Zydus appoints Punit Patel as President & CEO to lead its...
Punit will be responsible for the business operations of all Zydus entities in North America which include generics, injectables and specialty business, rare and orphan disease portfolio
Zydus to present on ZYIL1 at the International Congress of Parkinson’s...
ZYIL1 decreased α synuclein expression and improved motor function in non-clinical models
of Parkinson’s Disease
Zydus Lifesciences acquires 6.5% stake in Mylab via its subsidiary ZAHIL
The acquisition represents collective vision to transform healthcare by combining therapeutic expertise in human formulations and diagnostic capabilities of the two companies